FY2025 · ended Dec 31, 2025 · Revenue $41,000, +105.0% YoY · Filed Mar 6, 2026
Altimmune, Inc. (ALT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $41,000 and a net loss of $88.1 million. Free cash flow was -$67.5 million. As of Jun 30, 2026 it held $518.5 million in cash and investments and $36.0 million in total debt.
Revenue
$41,000
+105.0% vs prior year
Net income
$-88.09M
+7.3% vs prior year
Operating cash flow (TTM)
$-76.51M
+6.2% vs year-ago TTM
Free cash flow (TTM)
$-76.56M
+6.2% vs year-ago TTM
EPS
$-1.00
+25.4% vs prior year
Dividend per share
None
Shares outstanding
130.07M
+68.9% vs prior year
Net cash
$482.51M
as of Jun 30, 2026
Operating margin
-230461.0%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1326190
- Former names
- PHARMATHENE, INC (until May 3, 2017); HEALTHCARE ACQUISITION CORP (until Oct 15, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.4M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M |
| Diluted EPS | -$1.00 | -$1.34 | -$1.66 | -$1.81 | -$2.35 |
| Operating cash flow | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M |
| Free cash flow | -$67.5M | — | -$75.9M | -$62.7M | -$90.4M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M |
| Stockholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M |
| Cash and investments | $273.5M | $131.9M | $197.8M | $184.9M | $190.3M |
| Total debt | $35.7M | $1.7M | $671,000 | $5.7M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
New debt
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 28, 2026 | Jul 28, 2026 |
All 1001 Altimmune, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.